Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Journal article published in 2021 by
Christoph R. Kimmich,
Tobias Terzer,
Axel Benner,
Timon Hansen,
Alexander Carpinteiro,
Tobias Dittrich,
Kaya Veelken,
Anna Jauch,
Stefanie Huhn,
Marco Basset 
,
Hartmut Goldschmidt,
Carsten Müller‐Tidow,
Stefan O. Schönland,
Ute Hegenbart
,
Hartmut Goldschmidt,
Carsten Müller‐Tidow,
Stefan O. Schönland,
Ute Hegenbart
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 